We compared our candidate drugs to known anti-melanoma and NO-based drugs using publicly available drugs screens and high-throughput CRISPR data and experimentally validated six of these candidates in BRAF and NRAS mutated cell lines in mono and combination treatment with BRAF/MEK inhibitors. This evidence concerns the gene BRAF and melanoma.